NCT00436800View on ClinicalTrials.gov

Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions

Nasopharyngeal Neoplasms

Interventions

DRUG

Gemcitabine

1000mg/m² over 10mg/m²/min

DRUG

Oxaliplatin

100 mg/m² over 2 hours.

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Hong Kong

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Sanofi

INDUSTRY